Literature DB >> 15756304

Behavioral tolerance to lysergic acid diethylamide is associated with reduced serotonin-2A receptor signaling in rat cortex.

Paul J Gresch1, Randy L Smith, Robert J Barrett, Elaine Sanders-Bush.   

Abstract

Tolerance is defined as a decrease in responsiveness to a drug after repeated administration. Tolerance to the behavioral effects of hallucinogens occurs in humans and animals. In this study, we used drug discrimination to establish a behavioral model of lysergic acid diethylamide (LSD) tolerance and examined whether tolerance to the stimulus properties of LSD is related to altered serotonin receptor signaling. Rats were trained to discriminate 60 microg/kg LSD from saline in a two-lever drug discrimination paradigm. Two groups of animals were assigned to either chronic saline treatment or chronic LSD treatment. For chronic treatment, rats from each group were injected once per day with either 130 microg/kg LSD or saline for 5 days. Rats were tested for their ability to discriminate either saline or 60 microg/kg LSD, 24 h after the last chronic injection. Rats receiving chronic LSD showed a 44% reduction in LSD lever selection, while rats receiving chronic vehicle showed no change in percent choice on the LSD lever. In another group of rats receiving the identical chronic LSD treatment, LSD-stimulated [35S]GTPgammaS binding, an index of G-protein coupling, was measured in the rat brain by autoradiography. After chronic LSD, a significant reduction in LSD-stimulated [35S]GTPgammaS binding was observed in the medial prefrontal cortex and anterior cingulate cortex. Furthermore, chronic LSD produced a significant reduction in 2,5-dimethoxy-4-iodoamphetamine-stimulated [35S]GTPgammaS binding in medial prefrontal cortex and anterior cingulate cortex, which was blocked by MDL 100907, a selective 5-HT2A receptor antagonist, but not SB206553, a 5-HT2C receptor antagonist, indicating a reduction in 5-HT2A receptor signaling. 125I-LSD binding to 5-HT2A receptors was reduced in cortical regions, demonstrating a reduction in 5-HT2A receptor density. Taken together, these results indicate that adaptive changes in LSD-stimulated serotonin receptor signaling may mediate tolerance to the discriminative stimulus effects of LSD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15756304     DOI: 10.1038/sj.npp.1300711

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  10 in total

1.  Pharmacology of ayahuasca administered in two repeated doses.

Authors:  Rafael G Dos Santos; Eva Grasa; Marta Valle; Maria Rosa Ballester; José Carlos Bouso; Josep F Nomdedéu; Rosa Homs; Manel J Barbanoj; Jordi Riba
Journal:  Psychopharmacology (Berl)       Date:  2011-08-13       Impact factor: 4.530

Review 2.  Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research.

Authors:  David Bender; David J Hellerstein
Journal:  Psychopharmacology (Berl)       Date:  2022-01-13       Impact factor: 4.530

Review 3.  Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.

Authors:  Adam L Halberstadt
Journal:  Behav Brain Res       Date:  2014-07-15       Impact factor: 3.332

Review 4.  Psychedelics.

Authors:  David E Nichols
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

5.  A Single Dose of LSD Does Not Alter Gene Expression of the Serotonin 2A Receptor Gene (HTR2A) or Early Growth Response Genes (EGR1-3) in Healthy Subjects.

Authors:  Patrick C Dolder; Edna Grünblatt; Felix Müller; Stefan J Borgwardt; Matthias E Liechti
Journal:  Front Pharmacol       Date:  2017-06-28       Impact factor: 5.810

Review 6.  Novel Psychoactive Substances-Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs.

Authors:  Zurina Hassan; Oliver G Bosch; Darshan Singh; Suresh Narayanan; B Vicknasingam Kasinather; Erich Seifritz; Johannes Kornhuber; Boris B Quednow; Christian P Müller
Journal:  Front Psychiatry       Date:  2017-08-18       Impact factor: 4.157

7.  Microdosing psychedelics: More questions than answers? An overview and suggestions for future research.

Authors:  Kim Pc Kuypers; Livia Ng; David Erritzoe; Gitte M Knudsen; Charles D Nichols; David E Nichols; Luca Pani; Anaïs Soula; David Nutt
Journal:  J Psychopharmacol       Date:  2019-07-14       Impact factor: 4.153

8.  Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission.

Authors:  Danilo De Gregorio; Jelena Popic; Justine P Enns; Antonio Inserra; Agnieszka Skalecka; Athanasios Markopoulos; Luca Posa; Martha Lopez-Canul; He Qianzi; Christopher K Lafferty; Jonathan P Britt; Stefano Comai; Argel Aguilar-Valles; Nahum Sonenberg; Gabriella Gobbi
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-02       Impact factor: 11.205

9.  Tolerance to neurochemical and behavioral effects of the hallucinogen 25I-NBOMe.

Authors:  Monika Herian; Mateusz Skawski; Adam Wojtas; Małgorzata K Sobocińska; Karolina Noworyta; Krystyna Gołembiowska
Journal:  Psychopharmacology (Berl)       Date:  2021-05-25       Impact factor: 4.530

Review 10.  Neural mechanisms underlying psilocybin's therapeutic potential - the need for preclinical in vivo electrophysiology.

Authors:  Rebecca Smausz; Joanna Neill; John Gigg
Journal:  J Psychopharmacol       Date:  2022-05-30       Impact factor: 4.562

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.